News

People with transthyretin amyloid cardiomyopathy (ATTR-CM) live longer when the disease is diagnosed and treated earlier, with treatment benefits being much smaller in older…

The U.S. Food and Drug Administration (FDA) has lifted a clinical hold on a Phase 3 clinical trial testing the investigational gene-editing therapy, nexiguran ziclumeran…

More than half of adults with hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM), a condition marked by heart damage, also have multi-nerve damage, according to…

MRI scans detect brain changes in adults with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) before symptoms appear, according to a study. While these changes…

Treatments that target the transthyretin (TTR) protein, either by stabilizing it or reducing its production, were associated with about a one-third lower risk of death…

  The number of people diagnosed with transthyretin amyloidosis (ATTR) in the U.S. is climbing, a surge researchers attribute to better medical awareness and more…

Nerve ultrasound — a scan that uses high-frequency sound waves to create real-time images of the body’s nerves — may be used to monitor signs…

Adults who carry the Val30Met, or V30M, mutation — the most common cause of early-onset hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) — often develop heart…

RNA-targeted therapies — ones that zero in on molecules acting as messengers for genetic information in cells — are safe and effective at slowing the…

Polyneuropathy, or widespread nerve damage, occurs in both hereditary and wild-type transthyretin amyloidosis (ATTR), but the hereditary form, which includes familial amyloid polyneuropathy (FAP),…